Neurosciences encompasses a broad range of research from the molecular (e.g. aptamer research) to clinical (e.g. research into concussion from sports).
Our goal is to be internationally recognized in 3 areas (neuro-oncology, dementia and neurodegeneration and molecular psychiatry). We have a bench to bedside approach capitalizing on our quite unique staff profile ranging from basic biomedical scientists through pharmaceutics to clinicians.
We also focus on collaborations with our local charities and a network of researchers and clinicians across the world.
We have a significant local impact in our neuro-oncology research. One strand of our Molecular Psychiatry group is research into legal highs and this research has had an impact on the government drug policy. Our Dementia and Neurodegeneration group is funded by the company.
Clinical trials are very important as it allow us to evaluate the effectiveness of new drugs, new devices, preventative strategies or treatment strategies. It also enables us to discover better ways for patients' care.
- Learn more
Our mission remains constant as we endeavor to deliver novel medicines to patients with cancer, treating solid tumors with high unmet medical needs in well-defined patient populations that are currently not well supported.
- Learn more
Whether you're looking to manufacture toxicology batches or cGMP material for clinical trials, we can help you expedite molecules to clinic with full transparency.
- Learn more
2
Jan 2026
Placenta accreta spectrum (PAS) used to be a rare pregnancy condition, but it now affects roughly 14,000 pregnancies annually, posing a major cause of maternal death.
2
Jan 2026
Scientists and physicians can better assess precision genome editing technology using a new method made public today by St. Jude Children's Research Hospital. Significant amounts of time and resources spent improving CRISPR gene editing technology focus on identifying small off-target sites that pose a safety risk, which is also technically challenging.
2
Jan 2026
A new University of Toronto-led study has discovered a possible biomarker linked to multiple sclerosis (MS) disease progression that could help identify patients most likely to benefit from new drugs.
2
Jan 2026
As cesarean delivery (C-section) rates continue to rise worldwide, experts at NYU Langone Health are highlighting a surgical technique that may help lower the risk of long-term complications.